SoftOx Solutions is trading at NOK 0.12, down 5.74%, with no clear company-specific catalyst identified for September 11, 2026.
- The latest identifiable company announcement was the August 11 SIS-03 clinical-trial update, not a new September 10–11 development.
- Major U.S. indices were up more than 0.5%, so the move does not align with the broader-market backdrop.
- The decline remains unexplained, with limited evidence linking it to company, sector, or global factors.